Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

The FDA has signed off on Alnylam’s Amvuttra, also known as vutrisiran, as a treatment for cardiomyopathy of wild-type or hereditary ATTR-CM in adults to reduce the chance of cardiovascular ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an analysis of ALNY stock now.

The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare ...

“The FDA approval of AMVUTTRA for ATTR-CM marks a pivotal advancement for patients, providing a new and clinically differentiated treatment option that has been shown to improve ...

Other ATTR-CM pipeline candidates from Ionis and Intellia could follow. The FDA and EU had approved Amvuttra in 2022 for ATTR amyloidosis with polyneuropathy, a much rarer disease affecting about ...

Recent Developments and HELIOS-B Trial Results The cornerstone of Alnylam’s recent success has been the positive results from the HELIOS-B trial for Amvuttra in ATTR-CM patients. The trial ...